PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer

Marcelo V. Negrao, Vincent K. Lam, Alexandre Reuben, Maria Laura Rubin, Lara Lacerda Landry, Emily B. Roarty, Waree Rinsurongkawong, Jeff Lewis, Jack A. Roth, Stephen G. Swisher, Don L. Gibbons, Ignacio I. Wistuba, Vassiliki Papadimitrakopoulou, Bonnie S. Glisson, George R. Blumenschein, J. Jack Lee, John V. Heymach, Jianjun Zhang

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences